The Experts below are selected from a list of 29031 Experts worldwide ranked by ideXlab platform
F Soria - One of the best experts on this subject based on the ideXlab platform.
-
comparative sensitivity of urinary cyfra 21 1 urinary bladder cancer antigen tissue polypeptide antigen and NMP22 to detect bladder cancer
The Journal of Urology, 1999Co-Authors: Marta Sanchezcarbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., tissue polypeptide antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer antigen, 760.8 U./l. for tissue polypeptide antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer antigen quantitative and 80.2% for tissue polypeptide antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer antigen and 36% for tissue polypeptide antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
-
COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER ANTIGEN, TISSUE POLYPEPTIDE ANTIGEN AND NMP22 * TO DETECT BLADDER CANCER
The Journal of urology, 1999Co-Authors: Marta Sanchez-carbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., tissue polypeptide antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer antigen, 760.8 U./l. for tissue polypeptide antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer antigen quantitative and 80.2% for tissue polypeptide antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer antigen and 36% for tissue polypeptide antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
Enrique Herrero - One of the best experts on this subject based on the ideXlab platform.
-
comparative sensitivity of urinary cyfra 21 1 urinary bladder cancer antigen tissue polypeptide antigen and NMP22 to detect bladder cancer
The Journal of Urology, 1999Co-Authors: Marta Sanchezcarbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., tissue polypeptide antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer antigen, 760.8 U./l. for tissue polypeptide antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer antigen quantitative and 80.2% for tissue polypeptide antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer antigen and 36% for tissue polypeptide antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
-
COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER ANTIGEN, TISSUE POLYPEPTIDE ANTIGEN AND NMP22 * TO DETECT BLADDER CANCER
The Journal of urology, 1999Co-Authors: Marta Sanchez-carbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., tissue polypeptide antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer antigen, 760.8 U./l. for tissue polypeptide antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer antigen quantitative and 80.2% for tissue polypeptide antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer antigen and 36% for tissue polypeptide antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
Julian Megias - One of the best experts on this subject based on the ideXlab platform.
-
comparative sensitivity of urinary cyfra 21 1 urinary bladder cancer antigen tissue polypeptide antigen and NMP22 to detect bladder cancer
The Journal of Urology, 1999Co-Authors: Marta Sanchezcarbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., tissue polypeptide antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer antigen, 760.8 U./l. for tissue polypeptide antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer antigen quantitative and 80.2% for tissue polypeptide antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer antigen and 36% for tissue polypeptide antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
-
COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER ANTIGEN, TISSUE POLYPEPTIDE ANTIGEN AND NMP22 * TO DETECT BLADDER CANCER
The Journal of urology, 1999Co-Authors: Marta Sanchez-carbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., tissue polypeptide antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer antigen, 760.8 U./l. for tissue polypeptide antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer antigen quantitative and 80.2% for tissue polypeptide antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer antigen and 36% for tissue polypeptide antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
Antonio Mira - One of the best experts on this subject based on the ideXlab platform.
-
comparative sensitivity of urinary cyfra 21 1 urinary bladder cancer antigen tissue polypeptide antigen and NMP22 to detect bladder cancer
The Journal of Urology, 1999Co-Authors: Marta Sanchezcarbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., tissue polypeptide antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer antigen, 760.8 U./l. for tissue polypeptide antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer antigen quantitative and 80.2% for tissue polypeptide antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer antigen and 36% for tissue polypeptide antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
-
COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER ANTIGEN, TISSUE POLYPEPTIDE ANTIGEN AND NMP22 * TO DETECT BLADDER CANCER
The Journal of urology, 1999Co-Authors: Marta Sanchez-carbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., tissue polypeptide antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer antigen, 760.8 U./l. for tissue polypeptide antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer antigen quantitative and 80.2% for tissue polypeptide antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer antigen and 36% for tissue polypeptide antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
Marta Sanchez-carbayo - One of the best experts on this subject based on the ideXlab platform.
-
Citoqueratinas (UBC y CYFRA 21-1) y proteínas de la matriz nuclear (NMP22) como marcadores tumorales en la orina en el diagnóstico del cáncer vesical
Medicina clinica, 2000Co-Authors: Marta Sanchez-carbayo, Manuel Urrutia, María Luisa Hernández-cerceño, Jose Manuel González De Buitrago, José Alejandro NavajoAbstract:Fundamento Los marcadores tumorales en orina como UBC, CYFRA 21-1 y NMP22 son una alternativano invasiva para el diagnostico del cancer vesical.Se comparo la sensibilidad individual y combinada de los marcadores urinarios en la detecciondel cancer vesical con respecto a los metodos diagnosticos convencionales. Pacientes Y Metodos Se recogieron consecutivamente las orinas precistoscopia de 237 individuos:44 pacientes con sospecha de cancer vesical primario y 193 pacientes en seguimientode cancer vesical. UBC y NMP22 se cuantificaron por enzimoinmunoanalisis, CYFRA 21-1 porelectroquimioluminiscencia. Resultados Tomando como puntos de corte 9,7 μg/l para UBC, 5,4 ng/ml para CYFRA 21-1 y10,0 U/ml para NMP22 se encontraron unas sensibilidades del 70, del 69 y del 67%, paraunas especificidades del 95, del 94 y del 80%, respectivamente. Todos los marcadores tumoralesurinarios presentaron sensibilidades superiores a la de la citologia urinaria (7%), la presenciade microhematuria (62%) y hematuria franca (10%), cuyas especificidades fueron del99, del 78 y del 99%, respectivamente. La determinacion conjunta CYFRA 21-1 y NMP22 fuela combinacion que alcanzo la mayor sensibilidad (79%), ligeramente inferior a la determinacionsimultanea de los tres marcadores (80%). Conclusiones La sensibilidad de los marcadores tumorales UBC, CYFRA 21-1 y NMP22 en orinapara el diagnostico de cancer vesical puede justificar su determinacion en sustitucion de la citologiaurinaria. La similitud diagnostica de las citoqueratinas individualmente y en cada tipo depacientes en estudio desaconsejaria su determinacion simultanea. La determinacion conjuntade NMP22 y un marcador de citoqueratinas (CYFRA 21-1 o UBC) se presenta como la masaconsejable. Background The development of urinary tumor markers such as UBC, CYFRA 21-1 andNMP22 appeared to be non invasive alternative methods for the detection of bladder cancer.We compared the individual and combined sensitivity of the urinary tumor markers in the detectionof bladder cancer, contrasting them with the conventional diagnostic procedures. Patients and Methods 237 voided urines from subjects under risk for bladder cancer were collectedimmediately before the endoscopic examinations: 44 patients under suspicion of a primarybladder tumor and 193 patients under follow-up of a previous bladder cancer were included.UBC and NMP22 were measured by enzyme-immunoabsorbent-assays and CYFRA 21-1by an electrochemiluminiscent-immunoassay. Results Taking the cutoffs of 9.7 ig/l for UBC, 5.4 ng/ml for CYFRA 21-1 and 10.0 U/ml forNMP22 sensitivities were 70%, 69% and 67% for UBC, CYFRA 21-1 and NMP22 at specificitiesof 95%, 94% y 80%, respectively. All tumor markers showed higher sensitivities than urinarycytology (7%), microhematuria (62%) and gross hematuria (10%) at specificities of 99%,78% and 99%, respectively. The combinations of NMP22 plus CYFRA 21-1 reached the highestsensitivity (79%), slightly lower than simultaneously measuring the three tumor markers (80%). Conclusions The sensitivities of the urinary markers UBC, CYFRA 21-1 and NMP22 appearedto be high enough so as to substitute urinary cytology. The diagnostic similarity between cytokeratinsindividually and in each type of patients might not recommend their simultaneous determination.The combined measurement of NMP22 and one cytokeratin marker (CYFRA 21-1or UBC) appeared to be the most recommended.
-
COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER ANTIGEN, TISSUE POLYPEPTIDE ANTIGEN AND NMP22 * TO DETECT BLADDER CANCER
The Journal of urology, 1999Co-Authors: Marta Sanchez-carbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., tissue polypeptide antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer antigen, 760.8 U./l. for tissue polypeptide antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer antigen quantitative and 80.2% for tissue polypeptide antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer antigen and 36% for tissue polypeptide antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.